The FOURIER study has repeatedly shown that Repatha® is very effective at lowering cholesterol in sick patients, but an analysis in JAMA has shown that adding it to standard background therapy in patients with atherosclerosis is not cost effective. In order to be cost-effective, the price would need to be lowered substantially or treatment would need to be limited to a high-risk population group. Praluent® has already lowered its price to make the therapy more accessible and affordable for patients with the greatest health risk and unmet need. Will the science overcome the cost in the dyslipidemia market or could this indicate that there may be a cost ceiling for drug therapies?
Impress your clients and your boss. Subscribe today and follow the PDD narrative.